The First Affiliated Hospital ,Zhejiang University School of Medicine
Welcome,         Profile    Billing    Logout  
 0 Trials 
1 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Xuewu
NCT06504940: Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)

Recruiting
2
73
RoW
Orelabrutinib combined with bendamustine and rituximab, Orelabrutinib combined with obinutuzumab
First Affiliated Hospital of Zhejiang University
Marginal Zone Lymphoma
07/27
07/29
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zhang, Xuewu
NCT06504940: Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)

Recruiting
2
73
RoW
Orelabrutinib combined with bendamustine and rituximab, Orelabrutinib combined with obinutuzumab
First Affiliated Hospital of Zhejiang University
Marginal Zone Lymphoma
07/27
07/29

Download Options